Hemostatic coating in form of sponge or film (versions)

FIELD: pharmacology.

SUBSTANCE: invention is a hemostatic coating in the form of a sponge or film containing a base and an active substance zeolite, characterized by containing sodium alginate, a plasticizer and water as the base, and natural zeolite (Na2+, K2+)O⋅Al2O3⋅8SiO2⋅10H2O as an active substance, and the components in the hemostatic coating are in a certain ratio, in wt %.

EFFECT: expanded assortment of hemostatic sponges and films with pronounced hemostatic action and a significant decrease in the temperature of tissues at the place of agent contact with the wound surface.

4 cl, 25 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain: a) guanidine-based active substance, b) film-forming polymer, c) hydrophobic modifier of viscosity in quantity, sufficient for provision of composition for oral cavity care with time particle sedimentation more than 20 minutes, and d) oil carrier. Guanidine-based active substance preferably represents L-arginine. Film-forming polymer preferably represented GANTREZ. Hydrophobic modifier of viscosity preferably represents thickened mineral oil. Oil carrier preferably represents natural oil. Composition is enclosed in gelatine capsule. Method of teeth cleaning includes application on teeth of composition for oral cavity care in such a way that composition for oral cavity care cleans teeth. Device for oral cavity care, which contains: handle, fastened on handle head, where head has external surface and a row of teeth-cleaning elements, projecting outwards on external surface, and gelatine capsule, which contains composition for oral cavity care, located on head.

EFFECT: group of inventions makes it possible to increase teeth cleaning efficiency.

14 cl, 2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.

EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.

10 cl, 4 ex, 3 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely represents a method for producing an orally disintegrating tablet. The tablet is prepared by the method involving the stages of providing a liquid containing a drug substance, presenting a solid element having an at least one cavity formed thereof, cooling the solid element down to a temperature below a chilling temperature of the liquid, filling the cavity with the liquid, hardening the liquid in the cavity, rejecting heat from the liquid through a cavity wall by conductive heat transfer to form a solid granule containing a drug substance, with no active profiling along the whole surface of the granule, removing the granule from the cavity and drying the granule in vacuum.

EFFECT: developing the method for producing the orally disintegrating tablet.

15 cl, 4 ex, 6 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely represents a method for the therapy of respiratory symptom. The method involves administering a liquid composition containing a gel former and/or a mucoactive polymer, a non-menthol cooling substance; and contacting the oral mucosa with the liquid composition. The invention also describes liquid compositions applicable in the method for the therapy of a respiratory disease.

EFFECT: implementing the method provides improving the cooling properties of the cooling agent N-(4-cyanomethylphenyl)-n-menthane carboxamide in the liquid composition by combining the non-menthol cooling substance with the gel former.

14 cl, 2 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.

EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.

20 cl, 42 ex, 8 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate.

EFFECT: invention makes it possible to use aqueous balanced solution as effective means of external washing solution or as carrier solution for compatible electrolytes, nutrients and medications.

11 cl, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pro-apoptotic solid dispersion contains a compound, e.g. ABT-263 taken in a substantially non-crystalline form to inhibit Bcl-2 proteins and dispersed in a solid binding substance containing (a) a pharmaceutically acceptable water-soluble polymer carrier and (b) a pharmaceutically acceptable surfactant. A method for preparing this solid dispersion involving dissolving the compound, polymer carrier and surfactant in an acceptable dissolution medium and removing the dissolution medium to form the solid binding substance containing the polymer carrier and surfactant and possessing a compound dispersed therein in the substantially non-crystalline form.

EFFECT: solid dispersion is orally applicable in the individual in need thereof for treating a disease characterised by the overexpression of one or more anti-apoptotic Bcl-2 proteins, eg a malignant new growth.

22 cl, 6 ex, 2 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with a method of obtaining an elongated implant, where the ratio of the diameter to the length on the implant axis constitutes between 1:20 and 1:40, for the controlled and delayed release of a GnRH analogue of triptorelin acetate. In addition, the group of inventions deals with the elongated implant, obtained in accordance with the said method.

EFFECT: group of inventions provides good control over triptorelin release from the implant.

11 cl, 26 ex, 6 dwg, 11 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a method for the delivery of octreotide or its pharmaceutically acceptable salt into an individual, involving implanting the implanted device comprising a polyurethane polymer into the individual; the implanted drug delivery device for the octreotide acetate release by diffusion through a polyurethane polymer.

EFFECT: group of inventions provides high biocompatibility and biostability when used as an implant for the patients for the octreotide delivery to tissues or organs.

4 cl, 3 dwg, 5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular to a pharmaceutical composition in the form of the extrudate, containing at least one pharmaceutically active substance in the form of needles, characterised by the fact that the ratio of the particle size of the needle-like active substance to the diameter of strands constitutes at least 1:25.

EFFECT: invention makes it possible to obtain the more homogeneous extrudate.

11 cl, 13 ex, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining microcapsules.

4 ex

Up!